Shinor Biosciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 20-12-2024
- Paid Up Capital ₹ 2.30 M
as on 20-12-2024
- Company Age 3 Year, 27 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
as on 20-12-2024
- Satisfied Charges ₹ 7.00 M
as on 20-12-2024
About Shinor Biosciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.30 M.
The company currently has active open charges totaling ₹2.00 M. The company has closed loans amounting to ₹7.00 M, as per Ministry of Corporate Affairs (MCA) records.
Varesh Khanna and Romy Khanna serve as directors at the Company.
- CIN/LLPIN
U24299HR2021PTC100175
- Company No.
100175
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Dec 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Shinor Biosciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varesh Khanna  | Director | 27-Dec-2021 | Current |
| Romy Khanna | Director | 27-Dec-2021 | Current |
Financial Performance of Shinor Biosciences.
Shinor Biosciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Shinor Biosciences?
In 2022, Shinor Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shinor Herbals Private LimitedActive 3 years 3 monthsVaresh Khanna and Romy Khanna are mutual person
Charges (Loans)
₹2.00 M
₹7.00 M
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jul 2024 | Axis Bank Limited | ₹2.00 M | Open |
| 07 Sep 2022 | Others | ₹7.00 M | Satisfied |
How Many Employees Work at Shinor Biosciences?
Shinor Biosciences has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shinor Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shinor Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.